Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03507582
Other study ID # IRB16-00403
Secondary ID
Status Completed
Phase N/A
First received April 13, 2018
Last updated April 24, 2018
Start date April 2016
Est. completion date December 28, 2016

Study information

Verified date April 2018
Source Nationwide Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Children with hemophilia are exposed to intravenous (IV) procedures that cause pain/anxiety and distraction methods can be employed to improve the patient experience. Three-dimensional virtual reality (VR) environments can reduce distress related to procedures. To be utilized in a clinical setting, however, these devices must address infection control concerns and fit pediatric patients. Additionally, for use in hemophilia care, environments should encourage a subject to keep their hands/arms still to facilitate procedures. Nursing orchestration of the VR environment via an iPad dashboard has the potential to increase feasibility and acceptance by patients, families and providers of the VR experience without disrupting routine clinical care.


Description:

Patients with hemophilia A and B (HA/HB) are frequently treated with IV infusions of clotting factor concentrates to treat and prevent bleeding. Additionally they typically have at least yearly IV laboratory assessments. Pain and anxiety with needle related procedures particularly in children with hemophilia can lead to development of needle phobia, treatment avoidance and poor adherence to treatment regimens. Conventional virtual reality (VR) environments have been shown to reduce pain/anxiety in pediatric populations however in a clinical setting children with hemophilia have specific VR design needs that have not been addressed. Certain issues related to VR environments are related to the pediatric age range. These include the size and weight of VR headsets, the ease of donning and doffing headsets, and degree of engagement with VR environments. Hemophilia specific issues include the need for the VR experience to limit movement of the hands/arms to facilitate IV procedures, customization to prevent boredom/disengagement from repeated use and ability of clinical staff to trigger events via an orchestration dashboard that occur for the patients benefit at key times during IV procedures. Lastly, there are issues related to integration into a clinical setting. These include ability to integrate into clinical care without adversely affecting clinic flow, and infection control issues related to headset design.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date December 28, 2016
Est. primary completion date December 28, 2016
Accepts healthy volunteers No
Gender All
Age group 6 Years to 19 Years
Eligibility Inclusion Criteria:

1. Provide signed and dated informed consent form

2. Willing to comply with all study procedures and be available for the duration of the study

3. Diagnosed with Hemophilia A or B

4. Male or female, aged >6 years to <19 years

5. Subject and caregiver able to understand and speak English

6. Being seen for routine comprehensive hemophilia care visits during which an IV procedure is planned as standard of care.

Exclusion Criteria:

1. Inability to use the VR equipment (ie visual, cognitive or hearing impairment that would preclude engagement with the VR environment)

2. History of motion sickness as reported by patient or caregiver

3. History of poorly controlled seizures as reported by patient or caregiver

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Virtual Reality Distraction
This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
Standard of Care Distraction
This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.

Locations

Country Name City State
United States Nationwide Children's Hospital Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Nationwide Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nurse Orchestrated Virtual Reality Distraction The primary outcome of feasibility was assessed using a surrogate marker of feasibility which was duration of the IV procedure measured in minutes in both study arms. Procedure time was the length of time from the moment a patient was positioned for the procedure to the completion of the procedure. The study timer was incorporated in the study IPAD and timing was performed by the nurse orchestrator. Twelve months
Primary Standard of Care Distraction The primary outcome of feasibility was assessed using a surrogate marker of feasibility which was duration of the IV procedure measured in minutes in both study arms. Procedure time was the length of time from the moment a patient was positioned for the procedure to the completion of the procedure. The study timer was incorporated in the study IPAD and timing was performed by the nurse orchestrator. Twelve months
Secondary Effectiveness of the distraction technique Both patient groups assessed the effectiveness of their distraction techniques following the procedure by using a Visual analogue/FACES scale answering 3 anchored questions. 1) "Did the distraction technique keep you/your child /your patient engaged?" The anchors were 0=It really kept them engaged and 100=It really did not keep them engaged. 2) "Do you think the distraction technique/s changed you/your child/your patient's nervousness/anxiety level during the IV procedure?" The anchor of 0=it decreased nervousness/anxiety a lot, 100=it increased nervousness/anxiety a lot. 3) "How did the distraction technique/s affect pain during your/your child/your patient's IV procedure?" With 0=it made pain a lot better, 100=it made pain a lot worse. Twelve months
Secondary Usability and Likeability For patients randomized to the VR arm, data on the use of the VR equipment was recorded by the nurse orchestrator at the end of each procedure. Data was categorized if the participant wore the VR equipment: 1) during the entire procedure, 2) part of the procedure or 3) only prior to the procedure. Participants were also asked to rate usability of the VR equipment, by using the VAS/FACES scale to answer "How easy was it for you/your child/your patient to use the VR equipment?" A score of 0 represented really easy to use and a score of 100 correlated with really hard to use. Lastly, participants were asked to use the VAS?FACES scale to answer a likeability question by "How much would you/your child/your patient like to use VR for future IV procedures?" A score of 0 equated to they would really like to use VR again and 100 meant they would really not like to use it again. Twelve months
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1